Literature DB >> 11968052

Correlation of p21 gene codon 31 polymorphism and TNF-alpha gene polymorphism with nasopharyngeal carcinoma.

Ming-Hsui Tsai1, Wen-Chi Chen, Fuu-Jen Tsai.   

Abstract

Background p21 (WAF1/CIP1) is a downstream protein from p53 and can arrest the cell cycle at the G1/S phase in response to signal from p53. The most frequently seen polymorphic site is at codon 31, where a base change from AGC to AGA causes an amino acid change from serine to arginine. Tumor necrosis factor-alpha (TNF-alpha) is a cytokine that is secreted from macrophages, and is related to a sequence of events in the response to inflammation and cancer formation. The TNF-alpha gene promoter -308 G/A polymorphism has been reported to be associated with some cancers. In this study, these polymorphisms were proposed to be a candidate genetic marker of nasopharyngeal carcinoma (NPC). The distribution was analyzed in 47 NPC patients and a control group of 119 healthy people. The association of the p21 codon 31 polymorphism with NPC was detected by polymerase chain reaction (PCR) and restriction analysis by Blp I endonuclease, and calculated by the chi-square test. The TNF-alpha gene promoter -308 G/A polymorphism was identified by Nco I endonuclease. The distribution of the gene p21 codon 31 polymorphisms showed no significant difference between the two groups. The serine form of p21 codon 31 was more prominent in smokers than nonsmokers among the NPC patients (P < 0.05). There was no significant difference in the distribution of TNF-alpha gene promoter -308 G/A polymorphism between control and cancer patients. The results indicate that the gene p21 codon 31 polymorphism and TNF-alpha promoter -308 polymorphism are not correlated with NPC. However, the difference between smokers and nonsmokers suggests that an environmental factor may be involved in association with the p21 gene in the formation of NPC. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11968052      PMCID: PMC6808169          DOI: 10.1002/jcla.10032

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  33 in total

1.  A population-based case-control study of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis.

Authors:  D Wingerchuk; Q Liu; J Sobell; S Sommer; B G Weinshenker
Journal:  Neurology       Date:  1997-08       Impact factor: 9.910

2.  Transformation in vitro of a nontumorigenic rat urothelial cell line by tumor necrosis factor-alpha.

Authors:  M Okamoto; R Oyasu
Journal:  Lab Invest       Date:  1997-08       Impact factor: 5.662

3.  Novel polymorphism in p21(waf1/cip1) cyclin dependent kinase inhibitor gene: association with human esophageal cancer.

Authors:  R Bahl; S Arora; N Nath; M Mathur; N K Shukla; R Ralhan
Journal:  Oncogene       Date:  2000-01-20       Impact factor: 9.867

4.  Immunoexpression of tumour necrosis factor-alpha and its receptors 1 and 2 correlates with proliferation/apoptosis equilibrium in normal, hyperplasic and carcinomatous human prostate.

Authors:  M P de Miguel; M Royuela; F R Bethencourt; L Santamaría; B Fraile; R Paniagua
Journal:  Cytokine       Date:  2000-05       Impact factor: 3.861

Review 5.  Etiology of nasopharyngeal carcinoma: a review.

Authors:  A Hildesheim; P H Levine
Journal:  Epidemiol Rev       Date:  1993       Impact factor: 6.222

6.  An association in non-insulin-dependent diabetes mellitus subjects between susceptibility to retinopathy and tumor necrosis factor polymorphism.

Authors:  K Hawrami; G A Hitman; M Rema; C Snehalatha; M Viswanathan; A Ramachandran; V Mohan
Journal:  Hum Immunol       Date:  1996-03       Impact factor: 2.850

7.  D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA.

Authors:  Y Xiong; H Zhang; D Beach
Journal:  Cell       Date:  1992-10-30       Impact factor: 41.582

8.  Tumor necrosis factor-alpha allelic frequency and chromosome 6 allelic imbalance in patients with colorectal cancer.

Authors:  R Honchel; S McDonnell; D J Schaid; S N Thibodeau
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

9.  No point mutation but a codon 31ser-->arg polymorphism of the WAF-1/CIP-1/p21 tumor suppressor gene in nasopharyngeal carcinoma (NPC): the polymorphism distinguishes Caucasians from Chinese.

Authors:  Y Sun; A Hildesheim; H Li; Y Li; J Y Chen; Y J Cheng; R B Hayes; N Rothman; W F Bi; Y Cao
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1995 Apr-May       Impact factor: 4.254

10.  Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes.

Authors:  H Zhang; Y Xiong; D Beach
Journal:  Mol Biol Cell       Date:  1993-09       Impact factor: 4.138

View more
  7 in total

1.  TNF-α-308G/A polymorphisms and nasopharyngeal cancer risk: a meta-analysis.

Authors:  Li Xie; Xiao-Nan Liang; Yan Deng; Xue Qin; Shan Li
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-11-25       Impact factor: 2.503

2.  Polymorphism at P21 codon 31 and dinucleotide polymorphism of P73 gene and susceptibility to bladder cancer in individuals from North India.

Authors:  Praveen Kumar Jaiswal; Vibha Singh; Rama Devi Mittal
Journal:  Indian J Hum Genet       Date:  2013-07

3.  Association between p21 Ser31Arg polymorphism and cancer risk: a meta-analysis.

Authors:  Hongxia Ma; Ziyuan Zhou; Sheng Wei; Qingyi Wei
Journal:  Chin J Cancer       Date:  2011-04

Review 4.  The interplay of host genetic factors and Epstein-Barr virus in the development of nasopharyngeal carcinoma.

Authors:  Maria Li Lung; Arthur Kwok Leung Cheung; Josephine Mun Yee Ko; Hong Lok Lung; Yue Cheng; Wei Dai
Journal:  Chin J Cancer       Date:  2014-11

Review 5.  No association of TNF-α-308G/A polymorphisms with head and neck cancer risk: A PRISMA-compliant meta-analysis.

Authors:  Cheng Yuan; Xin-Hua Xu; Lu Xu; Yang Liu; Min Sun; Li-Hua Ni; Xiao-Long Wang; Zhuo Chen; Kun Zhang; Guang Zeng
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

6.  Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

Authors:  Hideaki Tahara; Marimo Sato; Magdalena Thurin; Ena Wang; Lisa H Butterfield; Mary L Disis; Bernard A Fox; Peter P Lee; Samir N Khleif; Jon M Wigginton; Stefan Ambs; Yasunori Akutsu; Damien Chaussabel; Yuichiro Doki; Oleg Eremin; Wolf Hervé Fridman; Yoshihiko Hirohashi; Kohzoh Imai; James Jacobson; Masahisa Jinushi; Akira Kanamoto; Mohammed Kashani-Sabet; Kazunori Kato; Yutaka Kawakami; John M Kirkwood; Thomas O Kleen; Paul V Lehmann; Lance Liotta; Michael T Lotze; Michele Maio; Anatoli Malyguine; Giuseppe Masucci; Hisahiro Matsubara; Shawmarie Mayrand-Chung; Kiminori Nakamura; Hiroyoshi Nishikawa; A Karolina Palucka; Emanuel F Petricoin; Zoltan Pos; Antoni Ribas; Licia Rivoltini; Noriyuki Sato; Hiroshi Shiku; Craig L Slingluff; Howard Streicher; David F Stroncek; Hiroya Takeuchi; Minoru Toyota; Hisashi Wada; Xifeng Wu; Julia Wulfkuhle; Tomonori Yaguchi; Benjamin Zeskind; Yingdong Zhao; Mai-Britt Zocca; Francesco M Marincola
Journal:  J Transl Med       Date:  2009-06-17       Impact factor: 5.531

7.  Tumor necrosis factor-alpha promoter polymorphism 308 G/A is not significantly associated with esophageal cancer risk: a meta-analysis.

Authors:  Ming Luo; Yuan Yang; Dongmei Luo; Liang Liu; Yuening Zhang; Feifan Xiao; Jingcheng Yang; Chengdong Zhang; Shen Fu; Zhiguo Luo
Journal:  Oncotarget       Date:  2016-11-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.